ByTrending Posts
Roche’s Gazyva Wins Second FDA Priority Review in…
Key Highlights A Landmark Regulatory Milestone for a Disease With No Approved Treatments Roche’s announcement that the FDA…
Can Attovia Therapeutics’ Nasdaq IPO Signal a Broader…
Key Highlights A Landmark Filing Reflecting Renewed Confidence in Biopharma Innovation Attovia Therapeutics’ decision to file for a…
Can OpenLoop’s Acquisition of Hey Revia Redefine How…
Key Highlights A Landmark Acquisition Strengthening OpenLoop’s Virtual Care Ecosystem OpenLoop, the Iowa-based telehealth infrastructure company known for…
Is the $2.5 Billion Insilico Medicine-Bora Pharmaceuticals Alliance…
Key Highlights A Landmark Alliance Bridging AI Discovery and Global Manufacturing In a move set to reshape the…
Can Sanofi’s Twin Lawsuits Against Pfizer and Moderna…
Key Highlights Two Companies, One Shared Technology Dispute Sanofi’s complaints, filed as Translate Bio Inc v. Pfizer Inc…
Pfizer’s $10 Billion Innovent Alliance: Is China Now…
Key Highlights A Broad Multidrug Alliance Built for Scale The agreement spans up to 12 programs, eight originating…
Can J&J’s Newly FDA-Approved Dual-Energy Ablation Catheter Help…
Key Highlights A Strategic Answer to Lost PFA Ground Johnson & Johnson enters the U.S. dual-energy ablation market…
J&J’s $1 Billion Firefly Bio Buy: Has Big…
Key Highlights A Novel Modality for a Notoriously Hard Target At the center of the acquisition is Firefly…
Can a Single Injection Change Everything? Novartis’s Itvisma…
Key Highlights Closing a Long-Standing Treatment Gap Itvisma’s approval extends gene replacement therapy to an SMA population that…
Trending Posts
Latest Stories
Roche’s Gazyva Wins Second FDA Priority Review in Months — Is Obinutuzumab Becoming Nephrology’s Next Blockbuster?
Key Highlights A Landmark Regulatory Milestone for a Disease With No Approved Treatments Roche’s announcement…
Can Attovia Therapeutics’ Nasdaq IPO Signal a Broader Biotech Funding Revival Backed by Goldman Sachs and Deep Track Capital?
Key Highlights A Landmark Filing Reflecting Renewed Confidence in Biopharma Innovation Attovia Therapeutics’ decision to…
Can OpenLoop’s Acquisition of Hey Revia Redefine How AI Automates Telehealth Communication for Thousands of Providers?
Key Highlights A Landmark Acquisition Strengthening OpenLoop’s Virtual Care Ecosystem OpenLoop, the Iowa-based telehealth infrastructure…
Is the $2.5 Billion Insilico Medicine-Bora Pharmaceuticals Alliance the Blueprint for AI-Native Pharma’s Next Decade?
Key Highlights A Landmark Alliance Bridging AI Discovery and Global Manufacturing In a move set…
Gallery
